Moderna IncMRNA
▲ ポジティブ技術資本規制関連度
Positive Phase 3 INTerpath-001 results for its personalized cancer vaccine intismeran autogene drove the 9.4% jump.
資産への影響 3
Biotech & Genomic Medicine
Moderna Inc
Merck & Company IncMRK
± 混在技術関連度
Keytruda is the combination partner in the positive Phase 3 melanoma trial, but the news is Moderna's vaccine data, not a Merck-specific development.
Critical Materials & Supply Chain
